Cryoservice manager runs the extra mile for Cancer Research

David Bryant completes 145-mile Grand Union Canal Run from Birmingham to London

The 145-mile Grand Union Canal Run is generally acknowledged as Britain’s longest continual race. Starting in Broad Street, Birmingham and finishing in Little Italy, London, competitors have to complete the race in 45 hours.

David Bryant, Cryoservice's business manager for science and industry, took 39 hours 15 minutes to complete the distance, running without sleep or a reasonable break.

‘The race is extremely challenging with only 40% of the starting line up normally finishing, so a hard training regime was required even to be in with a chance of reaching London,’ he said.

‘What kept me going was the knowledge that so many people had sponsored me and that the money raised would be going to a good cause.’

Bryant raised £3,350 for Cancer Research and came 16th.

Cryoservice, a supplier of specialist gases for science, leisure and industry, based in Worcester, UK, is a long-term business partner of Cancer Research UK and was recently short-listed for Supplier of the Year award, in recognition of its commitment and support of the organisation.

You may also like

Manufacturing

Automate Reactex glass reactor systems easily with Hitec Zang

Labtex, backed by more than 20 years of expertise in specialist laboratory and process chemistry equipment, is bringing advanced automation to its REACTEX glass reactor systems through innovative solutions from Hitec Zang
Training & Education

Celebrating 50 years of the Qualified Person (QP) and 35 Years of NSF Training

From York, where it all began, to today’s global stage—discover the story of the Qualified Person and the vital role they play in protecting patients
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Finance

Genmab to acquire Merus in $8bn deal to expand late-stage pipeline

The acquisition adds breakthrough therapy petosemtamab to Genmab’s portfolio, accelerating its shift to a wholly owned model and supporting multiple new drug launches by 2027
Manufacturing

Rezon Bio launches as European biologics CDMO with mirrored sites in Poland

New CDMO combines cost efficiency, digital innovation and EMA/FDA-audited facilities in Gdańsk and Warsaw to accelerate biologics development and commercialisation
Marketing

Theranexus rebrands as THX Pharma as it prepares to register and commercialise its drug candidates for rare neurological diseases

The company is entering a new strategic phase, focused on regulatory approval, early access and international commercialisation of its medicines TX01 and Batten-1
Manufacturing

RION engages Lonza to scale manufacturing exosome based therapeutics

Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions
Subscribe now